These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19555148)

  • 1. Cardiovascular risk and TZD: safe therapy for the elderly?
    Burt R; Townsend S; Armor B
    Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
    Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
    Punthakee Z; Bosch J; Dagenais G; Diaz R; Holman R; Probstfield J; Ramachandran A; Riddle M; Rydén LE; Zinman B; Afzal R; Yusuf S; Gerstein H;
    Diabetologia; 2012 Jan; 55(1):36-45. PubMed ID: 22038523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doubts as to the cardiovascular safety of rosiglitazone].
    Hoekstra JB; Bossuyt PM; de Vries JH
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
    Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
    JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
    Hsu JC; Ross-Degnan D; Wagner AK; Zhang F; Lu CY
    Clin Ther; 2015 Jul; 37(7):1420-1432.e1. PubMed ID: 25976425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones: the Forgotten Diabetes Medications.
    Lebovitz HE
    Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy with glitazones--a risk for cardiovascular disease?].
    Rottlaender D; Michels G; Erdmann E; Hoppe UC
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
    Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.